Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
14 07 2021
Historique:
received: 26 10 2020
accepted: 09 06 2021
entrez: 15 7 2021
pubmed: 16 7 2021
medline: 28 7 2021
Statut: epublish

Résumé

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

Identifiants

pubmed: 34262030
doi: 10.1038/s41467-021-24319-x
pii: 10.1038/s41467-021-24319-x
pmc: PMC8280160
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Neurofilament Proteins 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4304

Subventions

Organisme : Medical Research Council
ID : MR/S005145/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R21 AG056974
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056850
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG061566
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Neurology. 2019 Oct 22;93(17):e1647-e1659
pubmed: 31371569
Eur J Public Health. 2007 Apr;17(2):221-5
pubmed: 16857692
Alzheimers Dement (Amst). 2018 Apr 21;10:346-357
pubmed: 30175226
J Intellect Disabil Res. 2017 Sep;61(9):843-852
pubmed: 28664561
Lancet. 2020 Jun 27;395(10242):1988-1997
pubmed: 32593336
Lancet Neurol. 2018 Oct;17(10):860-869
pubmed: 30172624
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Neurology. 2015 Feb 3;84(5):500-7
pubmed: 25568295
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Lancet Neurol. 2020 May;19(5):422-433
pubmed: 32333900
Alzheimers Dement. 2017 Aug;13(8):841-849
pubmed: 28734653
Lancet Neurol. 2016 May;15(6):622-36
pubmed: 27302127
Mol Neurodegener. 2017 Sep 4;12(1):63
pubmed: 28866979
Mol Brain. 2019 Mar 28;12(1):26
pubmed: 30922367
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Acta Neuropathol. 2020 Sep;140(3):267-278
pubmed: 32720099
Mol Psychiatry. 2020 Jul 14;:
pubmed: 32665603
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Sci Transl Med. 2014 Mar 5;6(226):226ra30
pubmed: 24598588
Alzheimers Dement. 2019 Jun;15(6):742-753
pubmed: 30967340
Alzheimers Res Ther. 2019 Mar 21;11(1):26
pubmed: 30902060
Alzheimers Dement (N Y). 2019 Oct 14;5:597-609
pubmed: 31650016
N Engl J Med. 2012 Aug 30;367(9):795-804
pubmed: 22784036
Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824
pubmed: 31464088
Alzheimers Dement. 2018 Aug;14(8):989-997
pubmed: 29626426
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
JAMA Neurol. 2019 Feb 1;76(2):152-160
pubmed: 30452522
Alzheimers Dement (Amst). 2020 Jul 09;12(1):e12057
pubmed: 32671183

Auteurs

Alberto Lleó (A)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. alleo@santpau.cat.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. alleo@santpau.cat.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Möndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
UK Dementia Research Institute at UCL, London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

Jordi Pegueroles (J)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Thomas K Karikari (TK)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Möndal, Sweden.

María Carmona-Iragui (M)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Nicholas J Ashton (NJ)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Möndal, Sweden.
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.

Victor Montal (V)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Isabel Barroeta (I)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Juan Lantero-Rodríguez (J)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Möndal, Sweden.

Laura Videla (L)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Miren Altuna (M)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Bessy Benejam (B)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Susana Fernandez (S)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Silvia Valldeneu (S)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Diana Garzón (D)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Alexandre Bejanin (A)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Maria Florencia Iulita (MF)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Valle Camacho (V)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Santiago Medrano-Martorell (S)

Hospital del Mar-Universitat Autònoma Barcelona (UAB), Barcelona, Spain.

Olivia Belbin (O)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Jordi Clarimon (J)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Sylvain Lehmann (S)

The Institute for Neurosciences of Montpellier, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, INSERM, Montpellier, France.

Daniel Alcolea (D)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Rafael Blesa (R)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Möndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Juan Fortea (J)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. jfortea@santpau.cat.
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. jfortea@santpau.cat.
Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain. jfortea@santpau.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH